Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 -- -- Approximately 1,400 XPOVIO Prescriptions Fulfilled in the U.S. from Launch Through Year End 2019 -- NEWTON, Mass. , Jan.
View HTML
Toggle Summary Karyopharm to Present at the 38th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,000 shares of
View HTML
Toggle Summary Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NEWTON, Mass. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) seeking accelerated approval for XPOVIO®
View HTML
Toggle Summary Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting
-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma -- -- All Oral Regimen of Once-Weekly Selinexor with
View HTML
Toggle Summary Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting
-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst ® and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst ® -Naïve and Revlimid ® -Relapsed or -Refractory Myeloma with Progression-Free Survival of 12.2 Months -- -- Selinexor and Low Dose
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 84,000 shares of
View HTML
Toggle Summary Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Highlighted -- -- Other Key Presentations Include New Data from the STOMP Revlimid® Arm
View HTML
Toggle Summary Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
− XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO ® U.S. Net Product Sales of $12.8 Million with Over 500 Prescriptions Fulfilled as of September 30, 2019 – − Strengthened Balance Sheet with Cash Runway Expected to be Sufficient to Fund
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 169,500 shares of
View HTML